Ixeris dentata NAKAI reduces clinical score and HIF-1 expression in experimental colitis in mice

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Kim, Dae Seung ^a   Ko, Jang Ho ^a   Jeon, Yong Deok ^a   Han, Yo Han ^a   Kim, Hyun Ju ^b   Poudel, Amrit ^a   Jung, Hyun Ju ^a   Ku, Sae Kwang ^c   Kim, Su Jin ^c   Park, Sang Hyun ^d   Park, Jin Han ^e   Choi, Byung Min ^a   Park, Sung Joo ^f   Um, Jae Young ^b   Hong, Seung Heon ^a  

^a Wonkwang University   (South Korea)

^b Kyung Hee University   (South Korea)

^c Daegu Haany University   (South Korea)

^d Korea Atomic Energy Research Institute   (South Korea)

^e Gyeongju University   (South Korea)

^f Wonkwang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXTRAN SULFATE; HYPOXIA INDUCIBLE FACTOR 1; IXERIS DENTATA EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; FEMALE; HERBAL MEDICINE; INFLAMMATORY CELL; IXERIS DENTATA; MEDICINAL PLANT; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULCERATIVE COLITIS; UPREGULATION; WEIGHT REDUCTION;

EID: 84885339773     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/671281     Document Type: Article

References (41)

1. Li Y., de Haar C., Chen M., Deuring J., Gerrits M. M., Smits R., Xia B., Kuipers E. J., der Woude C., Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010 59 2 227 235 2-s2.0-77149155643 10.1136/gut.2009.184176
2. Ogata H., Hibi T., Cytokine and anti-cytokine therapies for inflammatory bowel disease. Current Pharmaceutical Design 2003 9 14 1107 1113 2-s2.0-0037268936 10.2174/1381612033455035 (Pubitemid 36443211)
3. Papadakis K. A., Targan S. R., Role of cytokines in the pathogenesis of inflammatory bowel disease. Annual Review of Medicine 2000 51 289 298 2-s2.0-0034005581 10.1146/annurev.med.51.1.289 (Pubitemid 30216038)
4. Mueller C., Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunology 2002 105 1 1 8 2-s2.0-0036161995 10.1046/j.1365-2567. 2002.01329.x (Pubitemid 34128034)
5. McCartney S. A., Mitchell J. A., Fairclough P. D., Farthing M. J. G., Warner T. D., Selective COX-2 inhibitors and human inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 1999 13 8 1115 1117 2-s2.0-0032853471 10.1046/j.1365-2036.1999.00585.x (Pubitemid 29374115)
6. Roberts P. J., Morgan K., Miller R., Hunter J. O., Middleton S. J., Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 2001 48 4 468 472 2-s2.0-0035080599 10.1136/gut.48.4.468 (Pubitemid 32234789)
7. Agoff S. N., Brentnall T. A., Crispin D. A., Taylor S. L., Raaka S., Haggitt R. C., Reed M. W., Afonina I. A., Rabinovitch P. S., Stevens A. C., Feng Z., Bronner M. P., The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. American Journal of Pathology 2000 157 3 737 745 2-s2.0-0034492927 (Pubitemid 32109366)
8. Haddad J. J., Science review: redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for hypoxia-inducible factor-1 α Critical Care 2003 7 1 47 54 2-s2.0-0037318947 10.1186/cc1840 (Pubitemid 36204269)
9. Taylor C. T., Colgan S. P., Hypoxia and gastrointestinal disease. Journal of Molecular Medicine 2007 85 12 1295 1300 2-s2.0-36849055112 10.1007/s00109-007-0277-z (Pubitemid 50004090)
10. Jung Y., Isaacs J. S., Lee S., Trepel J., Neckers L., IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. The FASEB Journal 2003 17 14 2115 2117 2-s2.0-0347334750
11. Robinson A., Keely S., Karhausen J., Gerich M. E., Furuta G. T., Colgan S. P., Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 2008 134 1 145 155 2-s2.0-37349048502 10.1053/j.gastro.2007.09.033 (Pubitemid 350309309)
12. Ahn E., Bang M., Song M., Park M., Kim H., Kwon B., Baek N., Cytotoxic and ACAT-inhibitory sesquiterpene lactones from the root of Ixeris dentata forma albiflora. Archives of Pharmacal Research 2006 29 11 937 941 2-s2.0-33845369567 (Pubitemid 44885768)
13. Oh S. H., Sung T. H., Kim M. R., Ixeris dentata extract maintains glutathione concentrations in mouse brain tissue under oxidative stress induced by kainic acid. Journal of Medicinal Food 2003 6 4 353 358 2-s2.0-1642494648 (Pubitemid 38114327)
14. Yi J., Hong S., Lee H., Won J., Kim J., Jeong D., Baek S., Lim J., Kim H., Ixeris dentata green sap inhibits both compound 48/80-induced aanaphylaxis-like response and IgE-mediated anaphylactic response in murine model. Biological & Pharmaceutical Bulletin 2002 25 1 5 9 2-s2.0-0036364154
15. Park E., Sung J., Trinh H., Bae E., Yun H., Hong S., Kim D., Lactic acid bacterial fermentation increases the antiallergic effects of Ixeris dentata. Journal of Microbiology and Biotechnology 2008 18 2 308 313 2-s2.0-46449100192
16. Blumberg R. S., Saubermann L. J., Strober W., Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Current Opinion in Immunology 1999 11 6 648 656 2-s2.0-0032707898 10.1016/S0952-7915(99) 00032-1
17. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., Nakaya R., A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990 98 3 694 702 2-s2.0-0025181580 (Pubitemid 20069706)
18. Hendrickson B. A., Gokhale R., Cho J. H., Clinical aspects and pathophysiology of inflammatory bowel disease. Clinical Microbiology Reviews 2002 15 1 79 94 2-s2.0-0036141470 10.1128/CMR.15.1.79-94.2002 (Pubitemid 34052583)
19. Murthy S. N. S., Cooper H. S., Shim H., Shah R. S., Ibrahim S. A., Sedergran D. J., Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Digestive Diseases and Sciences 1993 38 9 1722 1734 2-s2.0-0027275654 (Pubitemid 23271431)
20. Kim S., Kim M., Um J., Hong S., The beneficial effect of vanillic acid on ulcerative colitis. Molecules 2010 15 10 7208 7217 2-s2.0-78149427740 10.3390/molecules15107208
21. Hamamoto N., Maemura K., Hirata I., Murano M., Sasaki S., Katsu K., Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (icam-1)). Clinical and Experimental Immunology 1999 117 3 462 468 2-s2.0-0032793928 10.1046/j.1365-2249.1999.00985.x (Pubitemid 29398291)
22. Ardizzone S., Porro G. B., Biologic therapy for inflammatory bowel disease. Drugs 2005 65 16 2253 2286 2-s2.0-27644566447 10.2165/00003495- 200565160-00002 (Pubitemid 41571985)
23. Rufo P. A., Bousvaros A., Current therapy of inflammatory bowel disease in children. Pediatric Drugs 2006 8 5 279 302 2-s2.0-33750217972 10.2165/00148581-200608050-00002 (Pubitemid 44607534)
24. Sato K., Ohkura S., Kitahara Y., Ohama T., Hori M., Sato M., Kobayashi S., Sasaki Y., Hayashi T., Nasu T., Ozaki H., Involvement of CPI-17 downregulation in the dysmotility of the colon from dextran sodium sulphate-induced experimental colitis in a mouse model. Neurogastroenterology and Motility 2007 19 6 504 514 2-s2.0-34250215630 10.1111/j.1365-2982.2007. 00911.x (Pubitemid 46905395)
25. Ishiguro Y., Ohkawara T., Sakuraba H., Yamagata K., Hiraga H., Yamaguchi S., Fukuda S., Munakata A., Nakane A., Nishihira J., Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. Clinical Immunology 2006 120 3 335 341 2-s2.0-33746785986 10.1016/j.clim.2006.05.010 (Pubitemid 44175900)
26. Sandborn W. J., Targan S. R., Biologic therapy of inflammatory bowel disease. Gastroenterology 2002 122 6 1592 1608 2-s2.0-0036093570 (Pubitemid 34533555)
27. Myers K. J., Murthy S., Flanigan A., Witchell D. R., Butler M., Murray S., Siwkowski A., Goodfellow D., Madsen K., Baker B., Antisense oligonucleotide blockade of tumor necrosis factor α in two murine models of colitis. Journal of Pharmacology and Experimental Therapeutics 2003 304 1 411 424 2-s2.0-0037215607 10.1124/jpet.102.040329 (Pubitemid 36008955)
28. Naito Y., Takagi T., Uchiyama K., Kuroda M., Kokura S., Ichikawa H., Yanagisawa R., Inoue K., Takano H., Satoh M., Yoshida N., Okanoue T., Yoshikawa T., Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice. International Journal of Molecular Medicine 2004 14 2 191 196 2-s2.0-16644392805
29. Obermeier F., Kojouharoff G., Hans W., Schölmerich J., Gross V., Falk W., Interferon-gamma (IFN- γ)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clinical and Experimental Immunology 1999 116 2 238 245 2-s2.0-0032941175 10.1046/j.1365-2249.1999.00878.x (Pubitemid 29219719)
30. Fonseca-Camarillo G., Villeda-Ramirez M., Sanchez-Munoz F., IL-6 and TNF-a gene expression in the rectal mucosal of patients with chronic idiopathic ulcerative colitis and controls. Revista de Gastroenterología de México 2009 74 4 334 340
31. Morita I., Distinct functions of COX-1 and COX-2. Prostaglandins and other Lipid Mediators 2002 68-69 165 175 2-s2.0-0036669379 10.1016/S0090- 6980(02)00029-1 (Pubitemid 35247394)
32. Okayama M., Hayashi S., Aoi Y., Nishio H., Kato S., Takeuchi K., Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Digestive Diseases and Sciences 2007 52 9 2095 2103 2-s2.0-34547843601 10.1007/s10620-006-9597-z (Pubitemid 47246503)
33. Brune K., Hinz B., Selective cyclooxygenase-2 inhibitors: similarities and differences. Scandinavian Journal of Rheumatology 2004 33 1 1 6 2-s2.0-1542297649 10.1080/03009740310004766 (Pubitemid 38328075)
34. El-Medany A., Mahgoub A., Mustafa A., Arafa M., Morsi M., The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. European Journal of Pharmacology 2005 507 1-3 291 299 2-s2.0-12344281097 10.1016/j.ejphar.2004.11.036 (Pubitemid 40126866)
35. Lauritsen K., Laursen L. S., Kjeldsen J., Bukhave K., Hansen T. K., Rask-Madsen J., Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products. Advances in Experimental Medicine and Biology B 1995 371 1301 1306 2-s2.0-0029102980
36. Karhausen J., Furuta G. T., Tomaszewski J. E., Johnson R. S., Colgan S. P., Haase V. H., Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. The Journal of Clinical Investigation 2004 114 8 1098 1106 2-s2.0-9644302527 10.1172/JCI200421086 (Pubitemid 39578699)
37. Giatromanolaki A., Sivridis E., Kouskoukis C., Gatter K. C., Harris A. L., Koukourakis M. I., Hypoxia-inducible factors 1 α and 2 α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Research 2003 13 5 493 501 2-s2.0-0142120661 10.1097/00008390-200310000-00008 (Pubitemid 37266952)
38. Mariani F., Sena P., Marzona L., Riccio M., Fano R., Manni P., Gregorio C. D., Pezzi A., Leon M. P. D., Monni S., Pol A. D., Roncucci L., Cyclooxygenase-2 and Hypoxia-Inducible factor-1 α protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis. Cancer Letters 2009 279 2 221 229 2-s2.0-67349221477 10.1016/j.canlet.2009.02.001
39. Scortegagna M., Cataisson C., Martin R. J., Hicklin D. J., Schreiber R. D., Yuspa S. H., Arbeit J. M., HIF-1 α regulates epithelial inflammation by cell autonomous NF B activation and paracrine stromal remodeling. Blood 2008 111 7 3343 3354 2-s2.0-43549112364 10.1182/blood-2007-10-115758
40. Agarwal B., Swaroop P., Protiva P., Raj S. V., Shirin H., Holt P. R., Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 2003 8 6 649 654 2-s2.0-0242467932 10.1023/A:1026199929747 (Pubitemid 37411749)
41. Zhong H., Willard M., Simons J., NS398 reduces hypoxia-inducible factor (HIF)-1 α and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. International Journal of Cancer 2004 112 4 585 595 2-s2.0-7044227910 10.1002/ijc.20438 (Pubitemid 39425938)